BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37498672)

  • 1. Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.
    Devarajan R; Izzi V; Peltoketo H; Rask G; Kauppila S; Väisänen MR; Ruotsalainen H; Martínez-Nieto G; Karppinen SM; Väisänen T; Kaur I; Koivunen J; Sasaki T; Winqvist R; Manninen A; Wärnberg F; Sund M; Pihlajaniemi T; Heljasvaara R
    J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37498672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
    Nie J; Dang S; Zhu R; Lu T; Zhang W
    Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
    Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
    Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
    Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
    Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
    Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
    J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
    Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H
    Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.
    Zuo Y; Ulu A; Chang JT; Frost JA
    Breast Cancer Res; 2018 May; 20(1):41. PubMed ID: 29769144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
    Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
    J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of collagen types XVIII/endostatin and XV in normal, keratoconus, and scarred human corneas.
    Määttä M; Heljasvaara R; Sormunen R; Pihlajaniemi T; Autio-Harmainen H; Tervo T
    Cornea; 2006 Apr; 25(3):341-9. PubMed ID: 16633037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
    Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
    Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
    Lenferink AE; Simpson JF; Shawver LK; Coffey RJ; Forbes JT; Arteaga CL
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9609-14. PubMed ID: 10931950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
    Lyu C; Ye Y; Lensing MM; Wagner KU; Weigel RJ; Chen S
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34343132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells.
    Zhang P; Chen Y; Gong M; Zhuang Z; Wang Y; Mu L; Wang T; Pan J; Liu Y; Xu J; Liang R; Yuan Y
    Cell Physiol Biochem; 2018; 50(1):52-65. PubMed ID: 30326469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.
    Novitskiy SV; Forrester E; Pickup MW; Gorska AE; Chytil A; Aakre M; Polosukhina D; Owens P; Yusupova DR; Zhao Z; Ye F; Shyr Y; Moses HL
    Breast Cancer Res; 2014 Oct; 16(5):425. PubMed ID: 25280532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.
    Das S; Sondarva G; Viswakarma N; Nair RS; Osipo C; Tzivion G; Rana B; Rana A
    J Biol Chem; 2015 Aug; 290(35):21705-12. PubMed ID: 26152725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
    Farabaugh SM; Chan BT; Cui X; Dearth RK; Lee AV
    Cell Commun Signal; 2016 Oct; 14(1):25. PubMed ID: 27765041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.
    Schade B; Rao T; Dourdin N; Lesurf R; Hallett M; Cardiff RD; Muller WJ
    J Biol Chem; 2009 Jul; 284(28):19018-26. PubMed ID: 19435886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.